NRAS and colorectal carcinoma: Interestingly, both the Keynote 177 and Checkmate 142 studies of PD-1 mAbs in MSI-H/dMMR CRC showed numerically lower response rates in the KRAS/NRAS mutated subgroup, suggesting a possible negative correlation between RAS mutational status and immunotherapy response [35, 36].